Healthy volunteers help Fine-Tune experimental drug vonafexor
NCT ID NCT07251153
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing two forms of the experimental drug vonafexor (EYP651) in 40 healthy adults. The goal is to compare how the body processes the acid form versus the lysine salt form, and to check for interactions with other common medications. Results will guide future studies, but this trial does not test the drug's ability to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- vonafexor (EYP651)
- What this could lead to
- If successful, this study could help determine the best form of vonafexor for future trials and how it interacts with other drugs.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, not patients. Results may not predict effects in people with the target disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy male or female subject, aged 18-65 years inclusive. * Females of childbearing potential: commitment to use a highly effective method of birth control which result in a low failure rate. Females of non-childbearing potential: either at least 3 months surgically sterilized or at least 1-year postmenopausal confirmed by the follicle stimulating hormone (FSH) level. Males: commitment to use an adequate contraceptive method consistently and correctly. * Negative pregnancy test for childbearing potential women or FSH ≥ 40 IU/mL for postmenopausal women. * Non-smoker subject or smoker of maximum 5 cigarettes a day and able to stop during the study. * Body Mass Index (BMI) between 18 and 30 kg/m2 inclusive. * Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination). * Normal Blood Pressure and Heart Rate. * Normal ECG recording on a 12-lead ECG. * Laboratory parameters within the normal range of the laboratory (hematology, hemostasis, blood chemistry tests, urinalysis). * Normal dietary habits. * Signing a written informed consent prior to selection. * Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research. Exclusion Criteria: * Any relevant history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, haematological, neurologic, psychiatric, systemic or infectious disease. * Frequent headaches and / or migraine, recurrent nausea and / or vomiting. * Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension. * Blood donation in the 2 months before administration. * General anaesthesia in the 3 months before administration. * Presence or history of drug allergic condition and/or hypersensitivity. * Inability to abstain from intense muscular effort. * Any drug intake (except paracetamol and contraceptives) during the month prior to the first administration. * History or presence of drug or alcohol abuse (alcohol consumption \> 40 grams / day). * Excessive consumption of beverages with xanthine bases (\> 4 cups or glasses / day). * Positive Hepatitis B surface antigen or anti Hepatitis C Virus antibody, or positive results for Human Immunodeficiency Virus 1 or 2 tests. * Positive results for drugs of abuse tests. * No possibility of contact subject in case of emergency. * Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development. * Exclusion period of a previous study. * Administrative or legal supervision. * Subject who would receive more than 6'000 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adult male and female volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Eurofins Optimed
RECRUITINGGières, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can 10-Minute exercise snacks replace the gym marathon?
- Can a common ADHD drug truly sharpen a healthy mind? a trial puts it to the test
- Breathe deep: new study reveals how slow breathing calms your Body's nerves
- New Gene-Targeting shot shows promise for cholesterol control
- New drug ORX489 put to the test in healthy adults
- Exercise before surgery: could ReHIIT boost recovery for bowel cancer patients?